Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Nuclear Cardiology
Published in: Journal of Nuclear Cardiology 3/2016

01-06-2016 | Erratum

Erratum to: ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers

Authors: Milena J. Henzlova, MD, W. Lane Duvall, MD, Andrew J. Einstein, MD, Mark I. Travin, MD, Hein J. Verberne, MD

Published in: Journal of Nuclear Cardiology | Issue 3/2016

Login to get access

Excerpt

Please note the correction in Table 5 of the published article. Under the heading “Second Injection” and subhead “Activity (MBq),” the third row of numbers, which currently reads “888-1332,” should read “296-444”. The correct Table 5 is given here.
Table 5
Current SPECT myocardial perfusion imaging protocols: recommended radiopharmaceutical activities and their corresponding radiation effective doses
 
First injection
Second injection
Total
Total dose if
Given at
Activity (mCi)
Activity (MBq)
Dose (mSv)
Given at
Activity (mCi)
Activity (MBq)
Dose (mSv)
Dose (mSv)
Stress only (mSv)
Tc-99m protocols
 Tc-99m one-day stress-first/stress-only
Stress
8–12
296–444
2.0–3.0
(Rest)
24–36
888–1332
7.0–10.5
9.0–13.5
2.0–3.0
 Tc-99m one-day rest/stress
Rest
8–12
296–444
2.3–3.5
Stress
24–36
888–1332
6.1–9.1
8.4–12.6
n/a
 Tc-99m two-day stress/rest
Stress
8–12
296–444
2.0–3.0
(Rest)
8–12
296–444
2.3–3.5
4.3–6.5
2.0–3.0
 Tc-99m two-day stress/rest—large patient
Stress
18–30
666–1110
4.5–7.6
(Rest)
18–30
666–1110
5.2–8.7
9.8–16.3
4.5–7.6
 Tc-99m two-day rest/stress
Rest
8–12
296–444
2.3–3.5
Stress
8–12
296–444
2.0–3.0
4.3–6.5
n/a
 Tc-99m two-day rest/stress large patient
Rest
18–30
666–1110
5.2–8.7
Stress
18–30
666–1110
4.5–7.6
9.8–16.3
n/a
Tl-201 protocols
 Tl-201 stress/redistribution rest
Stress
2.5–3.5
92.5–129.5
10.9–15.3
n/a
n/a
n/a
n/a
10.9–15.3
10.9–15.3
 Tl-201 stress/redistribution rest/reinjection
Stress
2.5–3.5
92.5–129.5
10.9–15.3
Rest
1–2
37–74
4.4–8.8
15.3–24.1
n/a
 Tl-201 rest/redistribution
Rest
2.5–3.5
92.5–129.5
10.9–15.3
n/a
n/a
n/a
n/a
10.9–15.3
n/a
 Dual-isotope Tl-201 rest/Tc-99m stress
Rest
2.5–3.5
92.5–129.5
10.9–15.3
Stress
8–12
296–444
2.0–3.0
13.0–18.3
n/a
 Dual-isotope Tl-201 rest/Tc-99m stress—large patient
Rest
3.0–3.5
111–129.5
13.1–15.3
Stress
18–30
666–1110
4.5–7.6
17.7–22.9
n/a
I-123 protocol
 MIBG
Rest
10
370
4.6
n/a
n/a
n/a
n/a
4.6
n/a
Newer technology reduced-dose protocols
 Tc-99m one-day stress-first/stress-only
Stress
4–6
148–222
1.0–1.5
(Rest)
12–18
444–666
3.5–5.2
4.5–6.7
1.0–1.5
 Tc-99m one-day rest/stress
Rest
4–6
148–222
1.2–1.7
Stress
12–18
444–666
3.0–4.5
4.2–6.3
n/a
 Tc-99m two-day stress/rest
Stress
4–6
148–222
1.0–1.5
(Rest)
4–6
148–222
1.2–1.7
2.2–3.3
1.0–1.5
 Tc-99m two-day stress/rest—large patient
Stress
9–15
333–555
2.3–3.8
(Rest)
9–15
333–555
2.6–4.4
4.9–8.1
2.3–3.8
 Tc-99m two-day rest/stress
Rest
4–6
148–222
1.2–1.7
Stress
4–6
148–222
1.0–1.5
2.2–3.3
n/a
 Tc-99m two-day rest/stress—large patient
Rest
9–15
333–555
2.6–4.4
Stress
9–15
333–555
2.3–3.8
4.9–8.1
n/a
 Tl-201 stress/redistribution rest
Stress
1.3–1.8
48.1–66.6
5.7–7.9
n/a
n/a
n/a
n/a
5.7–7.9
5.7–7.9
 Dual-isotope Tl-201 rest/Tc-99m stress
Rest
1.3–1.8
48.1–66.6
5.7–7.9
Stress
4–6
148–222
1.0–1.5
6.7–9.4
n/a
 Dual-isotope Tl-201 stress/Tc-99m rest
Stress
1.3–1.8
48.1–66.6
5.7–7.9
(Rest)
4–6
148–222
1.2–1.7
6.9–9.6
5.7–7.9
Note that 1 mCi = 37 MBq, e.g., activity of 8 to 12 mCi = 8 × 37 to 12 × 37 MBq = 296 to 444 MBq. Note >3:1 ratio of activity of the second injection to that of the first injection. For example, the range for dose #1 is 8–12 mCi, and the range for dose #2 is 24–36 mCi. (Rest) denotes optional rest injection; it is recommended that stress images be reviewed by a nuclear cardiology physician prior to rest injection, and the rest injection only performed where clinically warranted.* Newer technology reduced-dose protocols have been studied for high-efficiency cameras,** and for image reconstruction with iterative reconstruction, depth-dependent resolution recovery, and noise modeling. Radiation effective dose values listed here are dose to a reference individual. Doses were determined using the most recent published International Commission on Radiological Protection (ICRP) organ dose coefficients, and ICRP Publication 103 tissue weighing factors. Tc-99m doses represent an average for sestamibi and tetrofosmin
* Gibson, Chang, Duvall77-79
** Einstein, Duvall73,74
*** DePuey72
…
Metadata
Title
Erratum to: ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers
Authors
Milena J. Henzlova, MD
W. Lane Duvall, MD
Andrew J. Einstein, MD
Mark I. Travin, MD
Hein J. Verberne, MD
Publication date
01-06-2016
Publisher
Springer US
Published in
Journal of Nuclear Cardiology / Issue 3/2016
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-016-0463-x

Other articles of this Issue 3/2016

Journal of Nuclear Cardiology 3/2016 Go to the issue

Editorial

Exercise and Bayes’ Theorem: Some things never go out of style

Erratum

Erratum to: Moving ahead with CZT technology

Editorial

High-risk coronary artery disease, but normal myocardial perfusion: A matter of concern?

Original Article

Prognostic value of heart rate response during regadenoson stress myocardial perfusion imaging in patients with end stage renal disease

Images that Teach

Utility of multimodality imaging in diagnosis and follow-up of aortitis

Editorial

Imaging moving heart structures with PET

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits